For a person with diabetes, were going to get a big one-two punch with Wegovy because its highly effective for controlling diabetes and helping with weight loss, Lazarus explains
Her work focuses on clinical strategies, patient care, and education in obesity treatment
In specific patients, with specific risk profiles, managed carefully, the case for short-term use is legitimate
Two symbols (**, ##, or $$) denote significant difference below 0.005, three symbols (***, ###, or $$$) denote significant below 0.0001
GLP-1 receptor agonists like semaglutide and tirzepatide have demonstrated weight loss results exceeding 15-22% of body weight in clinical trials
However, this also means they are not immediately ready for use